Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.
Volatility & Risk
Lucid Diagnostics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Lucid Diagnostics and Onconetix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Lucid Diagnostics and Onconetix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -959.76% | N/A | -119.57% |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
Valuation & Earnings
This table compares Lucid Diagnostics and Onconetix”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $5.45 million | 22.40 | -$58.01 million | ($0.47) | -1.28 |
| Onconetix | $810,000.00 | 3.57 | -$14.03 million | $248.12 | 0.00 |
Onconetix has lower revenue, but higher earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Lucid Diagnostics beats Onconetix on 9 of the 14 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
